On August 24, 2021, Bloomberg Law published “Life Sciences Anti-Corruption Enforcement Trends to Watch” by W. Warren Hamel and Nicholas A. Mongelluzzo. Anti-corruption enforcement by U.S. and foreign agencies against life sciences companies is trending upward. Since 2011, the DOJ and SEC have brought enforcement actions against 23 companies, resulting in $1.7 billion in fines, penalties, and disgorgement. The article highlights key takeaways from their piece, “Global Anti-Corruption Enforcement in the Life Sciences Industry: Trends, Risks & Best Practices in 2021.”
Click here to read the article from Bloomberg Law. Click here to read the full article.